(2S,3R,4R,5S,6R)-2-[4-Chloro-3-[(4-Ethoxyphenyl)Methyl]Phenyl]-6-Methylsulfanyloxane-3,4,5-Triol

Sotagliflozin is primarily indicated for:

• Management of Diabetes Mellitus: It is used in both type 1 and type 2 diabetes patients to improve glycemic control.
• Potential Cardiovascular Benefits: Emerging research suggests that sotagliflozin may also confer cardiovascular protection by improving heart function and reducing heart failure risk in diabetic patients.

The dual inhibition of SGLT1 and SGLT2 by sotagliflozin results in multiple beneficial effects:

• SGLT1 Inhibition: Reduces glucose absorption in the gastrointestinal tract, leading to lower postprandial blood glucose levels.
• SGLT2 Inhibition: Enhances urinary glucose excretion by preventing glucose reabsorption in the renal tubules. This mechanism is similar to that of selective SGLT2 inhibitors but with the added benefit of gastrointestinal action.

Clinical studies indicate that sotagliflozin effectively lowers glycated hemoglobin levels and has positive effects on body weight and blood pressure in diabetic patients.

Please email your required order quantity and detailed technical specifications to sales@.
Our sales team will promptly prepare an accurate quotation for your bulk order and provide a comprehensive pricing proposal.

All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.